Express Pharma

GSK announces £1 billion R&D investment over ten years to get ahead of infectious diseases in lower-income countries

This research will focus on new and disruptive vaccines and medicines to prevent and treat malaria, tuberculosis, HIV NTDs and AMR, which continue to have a devastating toll on the most vulnerable, accounting for more than 60 per cent of the disease burden in many lower-income countries

0 191

GSK yes